Uncategorized

A drug holds lung cancer at bay longer after surgery than standard chemotherapy, according to unpublished results of a new trial(link is external) in China. Patients in the trial were treated with gefitinib (Iressa), a drug that targets a faulty version of a molecule found on surface of some lung cancer cells called epidermal growth factor receptor (EGFR). These patients experienced a longer time without their lung cancer coming back after surgery than patients who received standard treatment. Those who received the targeted drug also reported fewer serious side effects. Professor Charles Swanton, from the Francis Crick Institute in London, part-funded by Cancer Research UK, said that the improvements were exciting and may lead to a change in how some lung cancer patients are treated.

See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-05-19-targeted-drug-delays-relapse-of-intermediate-stage-lung-cancer